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and almost all of the vasoconstrictor responses to acute NOSEndothelin and angiotensin mediate most glomerular re-
inhibition are prevented when both vasoconstrictor systemssponses to nitric oxide inhibition.
are blocked.Background. Endothelin (ET) and angiotensin mediate glo-
merular responses to systemic nitric oxide (NO) inhibition.
Acute systemic NO synthase (NOS) inhibition in the rat causes
marked increases in both preglomerular (RA) and efferent arte- Nitric oxide (NO) is a potent, physiologically impor-riolar (RE) resistances and a fall in the glomerular capillary tant vasodilator that maintains blood pressure (BP) andultrafiltration coefficient (Kf). In contrast, local intrarenal NOS
renal hemodynamics in the basal state [1–4]. Acute sys-inhibition increases RA, but has no effect on RE while producing
a similar Kf lowering effect as seen with systemic NOS inhibi- temic NO synthase (NOS) inhibition in the conscious rat
tion. These studies were designed to assess whether the increase produces a large sustained rise in BP and renal vascular
in RE during systemic NOS inhibition is mediated by endoge- resistance (RVR) [1, 5, 6]. In the anesthetized rat, acutenous ET and whether angiotensin II (Ang II) also contributes.
systemic NOS inhibition leads to complex changes inMethods. Micropuncture measurements were made before
glomerular hemodynamics, with marked increases inand during acute systemic NOS inhibition with N-monomethyl
l-arginine (NMA) alone, NMA 1 the nonpeptide ETA and both preglomerular (RA) and efferent arteriolar (RE)
ETB receptor antagonist, bosentan, NMA 1 the Ang II type resistances, such that glomerular BP (PGC) rises signifi-
1 receptor blocker, losartan, and NMA during combined bosen- cantly [7–9]. In contrast, local intrarenal NOS inhibitiontan and losartan.
has no effect on RE of cortical glomeruli while producingResults. The falls in single nephron glomerular filtration rate
a blunted increase in RA, and because systemic BP re-(SNGFR) and glomerular plasma flow seen with systemic NOS
inhibition were prevented by concomitant administration of mains constant, PGC changes little. A reduction in the
bosentan and losartan alone and in combination. The increases glomerular capillary ultrafiltration coefficient (Kf) occurs
in systemic blood pressure (BP), glomerular BP (PGC), RA, and with both acute systemic and intrarenal NOS inhibition,RE and the reduction in Kf seen with systemic NOS inhibition probably mediated by mesangial cell contraction, be-were attenuated by either bosentan or losartan. An attenuation
cause in vitro NO relaxes the glomerular mesangial cellsin the elevation in total renal vascular resistance seen with
systemic NOS inhibition was also observed with bosentan. [3, 10, 11]. These observations suggest that the increased
Combined ET and Ang II type 1 blockade completely pre- RE of cortical glomeruli seen with systemic NOS inhibi-
vented the increase in systemic BP, PGC, and RE and the fall tion is not due to direct inhibition of tonically producedin Kf with systemic NOS inhibition, leaving only a very attenu- NO in the efferent arteriole, but reflects some secondaryated rise in RA.
phenomenon resulting from systemic NOS inhibition.Conclusions. These findings suggest that endogenous ET
and Ang II partially mediate the glomerular hemodynamic The mechanism(s) whereby RE increases during sys-
responses (including the increased RE) to acute systemic NOS temic NOS inhibition has not yet been identified. It is
inhibition. The actions of ET and Ang II are mainly additive, possible that a vasoconstrictor system is potentiated or
activated during systemic NOS inhibition. There is evi-
dence to suggest participation of both endothelin (ET)1 Current address: F. Hoffmann-La Roche, Ltd., Pharma Division,
Preclinical Research, Basel, Switzerland. and the renin-angiotensin system in the glomerular he-
modynamic responses to acute systemic NOS inhibition.Key words: vasoconstriction, bosentan, losartan, N-monomethyl l-argi-
For example, acute systemic NOS inhibition potentiatesnine, efferent arteriolar resistance, single nephron glomerular filtration
rate. the vasoconstrictor actions of ET [12, 13] and enhances
the synthesis and release of ET [14, 15]. In the consciousReceived for publication May 26, 1998
rat, concomitant ET blockade attenuates the increasesand in revised form December 29, 1998
Accepted for publication January 21, 1999 in BP and RVR seen with acute systemic NOS inhibition
[6]. Angiotensin II (Ang II) contributes to the renal 1999 by the International Society of Nephrology
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vasoconstrictor response to acute systemic NOS inhibi- the following micropuncture measurements were made
in the superficial cortex: Exactly timed (two to threetion in situations in which the Ang II system is activated,
for example, by acute surgery and/or volume depletion minutes) collections of fluid from four to six superficial
proximal tubule segments were taken. Efferent arteriolaror when circulating Ang II levels are raised by infusion
[3, 16, 17]. blood was collected by puncture of three to five superfi-
cial efferent arterioles. Hydrostatic pressures were mea-The aim of these studies was to assess whether endoge-
nous ET and/or Ang II play a role in mediating the sured in surface proximal tubules, efferent arterioles, and
proximal segments of obstructed tubules (to measure PGCglomerular microcirculatory changes during acute sys-
temic NOS inhibition, with particular emphasis on the using the indirect stop flow pressure method, as de-
scribed previously) [20].increased RE. Specifically, we compared the effects on
glomerular hemodynamics of acute systemic NOS inhibi- At the end of the control measurements, one of the
following studies was carried out: Group I [N-mono-tion during concomitant ET or Ang II blockade, with
acute systemic NOS inhibition alone. These studies were methyl l-arginine (NMA); N 5 6] rats were given an
intravenous bolus of the NO synthesis inhibitor NMAconducted in the normal anesthetized, euvolemic (vol-
ume restored) rat using micropuncture of the cortical (30 mg/kg), followed by a continual intravenous infusion
of NMA (2 mg/kg/min). Group II [bosentan (BOS) 1nephrons.
NMA; N 5 7] received an intravenous bolus of BOS (10
mg/kg, F. Hoffmann-La Roche Ltd., Basel Switzerland),
METHODS
the mixed ETA/ETB receptor antagonist. This dose was
Studies were conducted on 26 male Sprague-Dawley chosen based on in vivo studies by Clozel et al, in which
rats (aged four to five months) obtained from Harlan the initial depressor and sustained pressor response to
Sprague-Dawley, Inc. (Indianapolis, IN, USA). Rats administered ET-1 was abolished [21]. Ten minutes after
were housed in laminar flow hoods and were allowed the administration of BOS, NMA was given, as in group
free access to food (approximately 20% protein, approxi- I. Group III [losartan (LOS) 1 NMA; N 5 8] received
mately 1% NaCl) and drinking water until the day of an intravenous bolus of the Ang II type 1 (AT1) receptor
the experiment. All animal procedures were approved blocker LOS (3 mg/kg; Du Pont Merck), and 10 minutes
by the West Virginia University Animal Care and Use later, NMA was given. Group IV (LOS 1 BOS 1 NMA)
Committee. received intravenous LOS followed immediately by in-
On the day of micropuncture, rats were anesthetized travenous BOS, and 10 minutes later, NMA was given.
with an intraperitoneal injection of thiobarbiturate, Inac- In all groups, 10 to 15 minutes after the last drug had been
tin (120 mg/kg; Research Biochemicals International, administered, two further urine clearances and complete
Natick, MA, USA). Further supplemental doses (5 to micropuncture measurements were made as described
10 mg/kg) were given intraperitoneally, as required dur- for control.
ing the experiment. When anesthetized, rats were placed At the end of all collections in groups II and III, the
on a temperature-controlled micropuncture table, and efficacy of antagonists was confirmed because the dose
the core temperature was maintained at 36 to 388C. The of BOS prevented both the initial fall and prolonged
rat was surgically prepared for glomerular micropunc- increase in BP in response to intravenous ET-1 (1 nmol/
ture studies using the euvolemic (volume restored) prep- kg), and LOS completely blocked the pressor response
aration [18]. Surgery included a tracheotomy, placement to intravenous Ang II (5 ng).
of intravenous lines in the left femoral and both jugular The activity of 3H-inulin was measured in aliquots of
veins for infusion of synthetic plasma, 3H-inulin (approxi- arterial and renal venous plasma, urine, and the entire
mately 100 to 150 mCi/hr), and drugs and a femoral tubule fluid sample and allowed the calculation of glo-
arterial line to monitor BP and to collect blood samples. merular filtration rate (GFR), renal plasma flow (RPF),
The left kidney was exposed through a ventral midline and single nephron GFR (SNGFR). Protein concentra-
and was left subcostal incision. The left ureter was cathe- tion of systemic and efferent arteriolar plasma was mea-
terized. The left renal vein was cannulated, and the left sured using a microadaptation of the Lowry method [22].
kidney was immobilized and prepared for micropuncture All of these measurements permit calculations of preglo-
as described previously [19]. The surface of the kidney merular (pA) and efferent arteriolar (pE) oncotic pres-
was illuminated and bathed in warm, 0.9% NaCl solution sures, RA and RE, RVR, and Kf. These techniques have
(34 to 368C). been described in detail by us elsewhere [19, 23].
After equilibration, control measurements were made Statistical analyses were by paired t-test within one
as follows: Two exactly timed urine collections (25 to 30 group and by one-way analysis of variance by the general
minute) were made. The urine volume was measured, linear models procedure using SAS [24]. Analysis of
and midpoint blood samples were taken from the femo- variance was done on the percentage change from con-
trol to compare the responses with NMA alone (groupral artery and renal vein. During the urine collections,
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Table 1. Summary of left kidney and single nephron hemodynamic responses in the normal anesthetized rat
GRF RPF RVR SNGFR QA PGC PT RA REBP mm Hg/ Kf
mm Hg ml/min FF (ml/min) nl/min mm Hg 1010dyn 3 sec 3 cm25 nl/sec/mm Hg
Group I (NMA; N 5 6)
Control 99 6 1 1.35 6 0.04 3.5 6 0.1 0.39 6 0.02 15 6 1 57 6 1 231 6 18 57 6 1 13 6 1 0.85 6 0.08 0.95 6 0.08 0.042 6 0.003
1NMA 131 6 2 1.16 6 0.06 2.3 6 0.1 0.50 6 0.02 29 6 2 44 6 2 120 6 14 79 6 3 14 6 2 1.96 6 0.30 2.87 6 0.26 0.019 6 0.001
P value , 0.001 , 0.01 , 0.005 , 0.005 , 0.001 , 0.005 , 0.001 , 0.001 NS , 0.005 , 0.001 , 0.001
Group II (BOS 1 NMA; N 5 7)
Control 101 6 1 1.82 6 0.06 5.1 6 0.4 0.37 6 0.03 11 6 1 67 6 6 220 6 21 62 6 1 14 6 1 0.82 6 0.08 1.17 6 0.10 0.044 6 0.003
1BOS 123 6 3a 1.72 6 0.08 3.5 6 0.2 0.49 6 0.02 19 6 1a 70 6 10a 197 6 30a 70 6 2a 14 6 1 1.31 6 0.17a 1.67 6 0.21a 0.037 6 0.005a
1NMA
P value , 0.001 NS , 0.05 , 0.05 , 0.001 NS NS , 0.005 NS , 0.01 , 0.01 , 0.05
Group III (LOS 1 NMA; N 5 8)
Control 100 6 1 1.52 6 0.08 4.5 6 0.5 0.36 6 0.02 13 6 1 54 6 3 176 6 15 59 6 2 14 6 1 1.06 6 0.10 1.36 6 0.13 0.043 6 0.003
1LOS 125 6 3a 1.59 6 0.16 3.3 6 0.4 0.50 6 0.02 22 6 3 56 6 4a 153 6 26a 73 6 2a 14 6 1 1.58 6 0.20a 2.23 6 0.30a 0.033 6 0.003a
1NMA
P value , 0.001 NS , 0.05 , 0.001 , 0.005 NS NS , 0.001 NS , 0.05 , 0.05 , 0.05
Group IV (LOS 1 BOS 1 NMA; N 5 5)
Control 108 6 3 1.17 6 0.07 4.1 6 0.4 0.30 6 0.02 15 6 2 39 6 2 119 6 11 65 6 2 12 6 1 1.66 6 0.26 2.27 6 0.32 0.026 6 0.002
LOS1BOS 111 6 6 1.09 6 0.10 4.1 6 0.4 0.27 6 0.02 15 6 2 40 6 2 113 6 11 60 6 3 11 6 1 2.11 6 0.31 2.37 6 0.32 0.030 6 0.002
1NMA
P value NS NS NS NS NS NS , 0.05 NS NS , 0.05 NS NS
Values are mean 6 se. Group I (NMA), acute systemic nitric oxide inhibition with N-monomethyl l-arginine (NMA) alone; Group II (BOS1NMA), combination
of both ET blockade with a non-peptide ETA and ETB receptor antagonist bosentan (BOS) and NMA; Group III (LOS 1 NMA), combination of both angiotensin
II inhibition with a selective AT1 receptor blocker losartan (LOS) and NMA; Group IV (LOS1BOS1NMA) combined angiotensin II AT1 and endothelin ETA and
ETB receptor antagonism during acute systemic NOS inhibition with NMA. Abbreviations are: BP, mean blood pressure; GFR, glomerular filtration rate; RPF, renal
plasma flow; FF, filtration fraction; RVR, renal vascular resistance; SNGFR, single nephron GFR; QA, glomerular plasma flow. PGC, glomerular blood pressure; PT,
proximal tubule pressure; RA, preglomerular arteriolar resistance; RE, efferent arteriolar resistance; Kf, glomerular capillary ultrafiltration coefficient; NS, not significant.
P values show significant difference by paired t-test.
a Significant difference between the change from control to experimental for BOS 1 NMA (Group II) or LOS 1 NMA (Group III) versus NMA alone (Group
I)
I) versus BOS 1 NMA (group II), LOS 1 NMA (group outer cortical single nephron population, BOS prevented
the falls in QA and SNGFR seen with acute systemicIII), or LOS 1 BOS 1 NMA (group IV). Statistical
significance was defined as a P of less than 0.05. Data NOS inhibition. BOS markedly attenuated the increases
in RA and RE and blunted the rise in PGC. BOS alsowere expressed as mean 6 se.
attenuated the fall in Kf seen with NMA alone.
In group III experiments, rats received a combination
RESULTS
of acute AT1 blockade with LOS and NMA. As shown
Data for whole kidney and single nephron function in in Table 1 and Figure 1, LOS attenuated the increase in
all groups are summarized in Table 1 and Figure 1. In BP and prevented the fall in GFR seen with NMA alone.
group I rats receiving NMA alone, BP increased substan- At the single nephron level, LOS prevented the falls in
tially and GFR fell slightly, whereas a more pronounced QA and SNGFR and attenuated the increases in RA, RE,
reduction in RPF occurred because of increased RVR; and PGC and the reduction in Kf seen with NMA alone.
thus, the filtration fraction (FF) rose. At the single neph- Group IV rats received combined AT1 and ETA/B
ron level, acute systemic NOS inhibition caused increases blockade during systemic NOS inhibition with NMA. As
in both RA and RE. As a result, QA decreased, but a large shown in Table 1 and Figure 1, blockade of both AT1
rise in PGC, resulting from the substantial increase in RE, and ET completely prevented the increases in BP, RVR,
meant that SNGFR fell only slightly. Proximal tubule and FF, as well as the fall in GFR seen in group I rats
pressure (PT) is unaffected by acute systemic NOS inhibi- receiving NMA alone. In outer cortical nephrons, com-
tion, thus the transglomerular hydrostatic pressure gradi- bined LOS and BOS completely prevented the falls in
ent (DP) increased. Kf was also markedly reduced with QA, SNGFR, and Kf, as well as the increase in RE and
acute systemic NOS inhibition. These observations con- PGC seen with acute systemic NOS inhibition. A markedly
firm earlier work by us and others [7, 8]. attenuated increase in RA persisted.
Group II rats received a combination of acute ET
blockade with the nonpeptide ETA and ETB receptor
DISCUSSIONantagonist BOS, and acute systemic NOS inhibition with
NMA. As shown in Table 1 and Figure 1, BOS attenu- In these studies, we confirmed earlier observations
that acute systemic NOS inhibition in the anesthetized,ated the increase in BP and RVR and prevented the fall
in GFR seen in group I rats receiving NMA alone. In the euvolemic rat produced a marked pressor and renal vaso-
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Fig. 1. The percentage change in mean arte-
rial blood pressure (BP), mean glomerular
blood pressure (PGC), afferent and efferent
arteriolar resistances (RA and RE, respec-
tively), and the glomerular capillary ultrafil-
tration coefficient (Kf) in the normal anesthe-
tized rat. Rats received acute systemic NO
synthesis inhibition (NOSI) alone, with NMA
(group I), combined endothelin blockade of
ETA and ETB receptors and NOSI with bosen-
tan and NMA (group II), combined NOSI
and angiotensin II AT1 receptor blockade with
losartan and NMA (group III), and NOSI dur-
ing combined ETA, ETB, and AT1 receptor
blockade (group IV). The asterisk denotes a
significant difference in the response versus
NOSI alone.
constrictor response [7–9]. Systemic NOS inhibition macula densa control) [3, 4, 7, 25]. The exaggerated rise
in RA during systemic NOS inhibition probably resultscaused complex glomerular hemodynamic changes, in-
cluding reductions in SNGFR and QA, large increases in from an autoregulatory response to the rise in BP. Most
workers conclude that renal autoregulation remains in-both RA and RE leading to a marked rise in PGC, and a
decline in Kf. However, some of the rise in RA and much tact during NOS inhibition [3, 4]. However, RE does not
participate in normal autoregulatory responses [26], andof the increased RE in the outer cortical nephrons was
indirect (that is, not due to inhibition of intrarenal NOS) thus, autoregulation is unlikely to account for the large
rise in RE with systemic NOS inhibition.because with local intrarenal administration of NOS in-
hibitor (in which systemic BP did not change), we re- An alternative explanation is that some underlying
vasoconstrictor system is activated and mediates the in-ported a smaller rise in RA and no increase in RE versus
systemic NOS inhibition [7]. The effect on Kf was main- crease in RE during systemic NOS inhibition. NO is a
major endogenous vasodilator that functionally counter-tained during local NOS inhibition, suggesting that tonic
control of cortical glomerular hemodynamics by NO is balances active vasoconstrictor systems. Both in vitro
and in vivo, acute NOS inhibition potentiates the vaso-confined to the mesangial cell (regulating Kf) and preglo-
merular resistance vessels (via vascular endothelial and constrictor responses to both ET and Ang II [2, 3, 6, 12,
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13]. Thus, these studies were designed to investigate the suggest that the glomerular microcirculatory changes,
including the increased RE during acute systemic NOSrole of endogenous ET and Ang II in mediating the
cortical glomerular hemodynamic responses, and partic- inhibition, are partially the result of secondary effects
of ET.ularly the rise in RE, to acute systemic NOS inhibition.
It should be noted that although in vivo and in vitro Therefore, when renal perfusion pressure (RPP) rises
because of NOS inhibition, the kidney exhibits an exag-studies have indicated that locally released NO has little
role in relaxing the efferent arteriole of superficial neph- gerated vasoconstriction mediated by ET. In separate
studies, we reported that even transient (5 min) exposurerons [7, 27], the situation is apparently different in the
juxtamedullary population, in which a direct vasodilatory of the kidney to a NOS inhibition-induced rise in RPP
leads to a prolonged (more than 40 min) renal vasocon-action of NO is seen at both RA and RE [28].
Endothelin is a potent renal vasoconstrictor that in- striction [38, 39]. The rise in RVR is not reversible de-
spite normalization of RPP with either vasodilators (NOcreases RA and RE both in vivo and in vitro, although
the relative magnitude of these effects varies according donor or Ca channel blocker) or by mechanical reduc-
tion. Recently, we reported that this “memory” of ato the experimental preparation [11, 27, 29–31]. ET can
also contract the mesangial cell and lower Kf when ad- transient NOS induced rise in RPP by the kidney is ET
mediated, because BOS restores normal renal vascularministered in high concentrations [11, 29]. Thus, ET ad-
ministration mimics the glomerular hemodynamic re- responses [39]. This prolonged ET-dependent rise in
RVR fits well with the extended vasoconstriction actionsponses to systemic NOS inhibition. However, acute ET
blockade in the normal rat produces a fall in PGC because of ET following binding to its vascular receptor [40, 41].
Administered Ang II also produces glomerular hemo-of an increase in RA [32]. This suggests that endogenous
ET tonically dilates, rather than contracts, the preglo- dynamic responses that closely resemble the response to
systemic NOS inhibition [3]. In this study, we found thatmerular arteriole via an ETB mediated effect [3, 10, 11],
probably secondary to endothelial ETB-stimulated NO concomitant Ang II inhibition with LOS also prevents
the decreases in SNGFR and QA and attenuates theand/or prostaglandin production [32].
Acute systemic NOS inhibition not only potentiates increases in BP, PGC, RA, and RE, and the reduction in
Kf seen with systemic NOS inhibition alone. These find-the vasoconstrictor actions of ET [12, 13], but also en-
hances the synthesis and release of ET [14, 15, 33]. In ings are consistent with earlier reports [9, 28], which
suggests that endogenous Ang II mediates some of theaddition, because the tonically active ETB-mediated re-
nal vasodilation is predominantly secondary to NO re- glomerular hemodynamic responses to acute systemic
NOS inhibition in the anesthetized animal and in the inlease in the rat (via endothelial ETB receptors), NOS
inhibition unveils the renal vasoconstrictor action of acti- vitro juxtamedullary nephron preparation.
These studies therefore show that inhibition of eithervated ETB receptors on vascular smooth muscles [13, 34,
35]. Furthermore, NO terminates the actions of ET, both ET or Ang II will eradicate much of the cortical glomeru-
lar hemodynamic responses to systemic NOS inhibition.by displacing ET from its receptor and by inhibiting
the postreceptor response to ET of calcium mobilization When both vasoconstrictor systems (ET and Ang II) are
blocked simultaneously, the pressor action of acute NOS[36]. Our previous studies suggested that the pressor
and renal vasoconstrictor actions of acute systemic NOS inhibition is eradicated. The renal vasoconstrictor re-
sponse is considerably attenuated, with the increase ininhibition in the conscious rat are partially mediated
by endogenous ET [6]. In the anesthetized rat, ETA- RE being abolished and only approximately 25% of the
increased RA being preserved. Thus, the acute glomeru-mediated vasoconstriction contributes to the pressor and
renal vasoconstrictor actions of acute systemic NOS inhi- lar hypertension seen with NMA is converted to a slight
fall in PGC when ET and Ang II are inhibited. Thesebition [37]. Thus, it is likely that some of the glomerular
hemodynamic responses to acute systemic NOS inhibi- findings implicate a major role for the combined actions
of ET and Ang II in mediating the peripheral and renaltion result from the unrestrained vasoconstrictor actions
of ET. vasoconstrictor responses to acute systemic NOS inhibi-
tion in the anesthetized, euvolemic rat. Only a smallIn these studies, we have confirmed our earlier report
[6] that concomitant ET blockade attenuates the in- fraction of the increased afferent arteriolar tone is appar-
ently mediated by removal of a direct vasodilatory actioncreases in BP and RVR seen with acute systemic NOS
inhibition. At the single nephron level, concomitant ET of NO. Based on the response to combined blockade,
most of the vasoconstrictor actions of ET and Ang II areblockade attenuates the segmental renal vasoconstrictor,
glomerular hypertensive, and Kf-lowering effects of sys- additive, although individual inhibition of the separate
vasoconstrictor agonists led to greater than 50% attenua-temic NOS inhibition. Of note, the increase in RE caused
by NMA was substantially reduced by ET blockade. tion of the increase in RA and RE. This appears paradoxi-
cal; how can each pathway be responsible for the major-Thus, the falls in SNGFR and QA with systemic NOS
inhibition were prevented by ET blockade. These results ity of the response? It is now becoming evident, however,
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